SCHEMBL17898268

SCHEMBL17898268

CN1CCC(c2ccc(N(C)c3ccc(Oc4nc(O)c5ccncc5n4)cc3C(F)(F)F)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 18/20 0.48
▸ PTK2 Q05397 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17898270 0.89 KDM4C (0.45) KDM4C
SCHEMBL17898278 0.87 KDM4C (0.55) KDM4C
SCHEMBL17898277 0.86 KDM4C (0.43) KDM4CPTK2
SCHEMBL29541993 0.82 KDM4C (0.52) KDM4C
SCHEMBL17891437 0.82 KDM4C (0.52) KDM4C
SCHEMBL17891432 0.82 KDM4C (0.68) KDM4C
SCHEMBL29542492 0.81 KDM4C (0.54) KDM4C
SCHEMBL17891443 0.81 KDM4C (0.54) KDM4C
SCHEMBL17898306 0.81 KDM4C (0.46) KDM4C
SCHEMBL17898279 0.80 KDM4C (0.39) KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208039-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-19 — — US disclosed
US-10202381-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-12 — — US disclosed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 — — US disclosed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 — — US disclosed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 — — US disclosed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 — — US disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885PTK2 3228/4885
US-10030017-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885PTK2 3228/4885
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885PTK2 3228/4885
US-10202381-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885PTK2 3228/4885
US-10208039-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885PTK2 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback